This is a single-center, open-label, randomized study to assess the plasma pharmacokinetic profile of LNZ101 and LNZ100.
To characterize the plasma pharmacokinetics and safety profile of LNZ101 and LNZ100 ophthalmic solutions in both eyes once a day for 8 days in healthy volunteers with presbyopia
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
30
LNZ101 (Aceclidine/Brimonidine) non-preserved ophthalmic solution
LNZ100 (Aceclidine) non-preserved ophthalmic solution
Site #101
Newport Beach, California, United States
Cmax
Maximum plasma concentrations of LNZ100 and LNZ101
Time frame: Day 1 and Day 8
Tmax
Time of maximum plasma concentrations of LNZ100 and LNZ101
Time frame: Day 1 and Day 8
AUC0-t
Area under the concentration-time curve from time 0 to time t of LNZ100 and LNZ100
Time frame: Day 1 and Day 8
AUC0-inf
Area under the concentration-time curve from time 0 to infinity of LNZ100 and LNZ101
Time frame: Day 1 and Day 8
T1/2
Terminal half-life of LNZ100 and LNZ101
Time frame: Day 1 and Day 8
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.